CanSino Biologics (CanSinoBIO) has announced the initiation of Phase I/II clinical trials in Indonesia for its restructured polio vaccine. This development marks a crucial step in the vaccine's journey toward potential licensure and deployment.
The Phase I portion of the clinical trial has already dosed its first subject. The study aims to evaluate the safety and immunogenicity of the restructured polio vaccine in the target population. Further details regarding the trial design, such as the number of participants and specific endpoints, were not disclosed in the announcement.
Polio remains a concern in various parts of the world, and new vaccine strategies are needed to eradicate the disease completely. CanSinoBIO's efforts to develop and test a novel polio vaccine candidate contribute to the global initiative to combat this infectious disease.
